Last reviewed · How we verify
CB-839 Tablets
At a glance
| Generic name | CB-839 Tablets |
|---|---|
| Also known as | Glutaminase inhibitor |
| Sponsor | Calithera Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (PHASE2)
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) (PHASE2)
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (PHASE1, PHASE2)
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (PHASE2)
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (PHASE1, PHASE2)
- A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-839 Tablets CI brief — competitive landscape report
- CB-839 Tablets updates RSS · CI watch RSS
- Calithera Biosciences, Inc portfolio CI